Significant Sales Growth
ImmuCell Corporation reported a 52% sales growth during both the fourth quarter of 2024 and the full year 2024 compared to the previous year, achieving $7.8 million in sales during the fourth quarter.
Increase in Gross Margin
Gross margin increased by 125% to $2.8 million in Q4 2024 compared to Q4 2023, and by 105% to $7.9 million for the year ended December 31, 2024, compared to 2023.
Positive EBITDA Turnaround
The company generated EBITDA of $1.3 million in Q4 2024 compared to negative EBITDA of $311,000 in Q4 2023, marking a positive swing of approximately $3.7 million for the year.
Improved Cash Position
The company raised net proceeds of almost $4.4 million through at-the-market offering, improving its cash position to $3.8 million as of December 31, 2024, from $979,000 at the end of 2023.
Re-Tain Product Development
ImmuCell is poised to revolutionize subclinical mastitis treatment with Re-Tain, pending FDA clearance for a controlled launch, following significant investment and development.